Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Update March 2022

Wolf, S. (2021): Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Update March 2022. Oncology Fact Sheet Nr. 41.

[thumbnail of Oncology Fact Sheet Nr.41_2nd Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
594kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WP Gynaecology > WP 440-468 Uterine diseases
Language:	English
Series Name:	Oncology Fact Sheet Nr. 41
Deposited on:	24 Mar 2021 16:50
Last Modified:	02 Mar 2022 23:52

Repository Staff Only: item control page